Search results
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
May 29, 2024 · A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. We are dedicated to improving human health by unlocking the power of the genome.
Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers.
At Illumina, our core values stem from innovation, discovery, and collaboration. As an executive team, we strive to deliver leading genomic technologies that enable boundless research discovery and pioneering personalized health.
Jan 10, 2022 · Illumina delivered a strong finish to 2021, with preliminary consolidated fourth quarter revenue of approximately $1.190 billion, up 25% year-over-year. This record revenue for the quarter reflected records across both instruments and consumables.
Sep 29, 2022 · Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum: The launch of NovaSeq™ 6000 Dx as the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, delivering the ...
Aug 18, 2021 · SAN DIEGO, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
Feb 7, 2023 · SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.
